Overview
- The U.S. State Department confirmed it had initiated a phased drawdown of PEPFAR support for South Africa, a move first reported and discussed publicly on Monday that could be completed in stages into early 2027.
- South African officials say they have not received formal final notice and stressed the government already pays about 90% of antiretroviral drugs while working on a self-reliance transition plan.
- Frontline groups report immediate harm from earlier phases of cuts, with more than 8,000 jobs lost and services disrupted in roughly 40% of public clinics in KwaZulu‑Natal, according to local NGO and reporting sources.
- UNAIDS and U.N. officials have publicly urged Washington to reconsider and researchers warn that an unmanaged withdrawal could cause hundreds of thousands of extra infections and tens of thousands of additional deaths by 2028.
- PEPFAR historically provided about $400 million a year and paid the salaries of roughly 15,000 program staff who run tracing, outreach and data systems, so experts say gaps could raise domestic health costs and complicate rollouts of new prevention tools such as long‑acting injections.